Your browser doesn't support javascript.
loading
The COMPASS Trial: Net Clinical Benefit of Low-Dose Rivaroxaban Plus Aspirin as Compared With Aspirin in Patients With Chronic Vascular Disease.
Steffel, Jan; Eikelboom, John W; Anand, Sonia S; Shestakovska, Olga; Yusuf, Salim; Fox, Keith A A.
Afiliación
  • Steffel J; Department of Cardiology, University Heart Center Zurich, Switzerland (J.S.).
  • Eikelboom JW; Population Health Research Institute, McMaster University and Hamilton Health Sciences, Canada (J.W.E., S.S.A., O.S., S.Y.).
  • Anand SS; Population Health Research Institute, McMaster University and Hamilton Health Sciences, Canada (J.W.E., S.S.A., O.S., S.Y.).
  • Shestakovska O; Population Health Research Institute, McMaster University and Hamilton Health Sciences, Canada (J.W.E., S.S.A., O.S., S.Y.).
  • Yusuf S; Population Health Research Institute, McMaster University and Hamilton Health Sciences, Canada (J.W.E., S.S.A., O.S., S.Y.).
  • Fox KAA; Centre for Cardiovascular Science, University of Edinburgh, United Kingdom (K.A.A.F.).
Circulation ; 142(1): 40-48, 2020 07 07.
Article en En | MEDLINE | ID: mdl-32436455

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Enfermedades Vasculares / Aspirina / Rivaroxabán Límite: Aged / Female / Humans / Male / Middle aged Idioma: En Revista: Circulation Año: 2020 Tipo del documento: Article Pais de publicación: Estados Unidos

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Enfermedades Vasculares / Aspirina / Rivaroxabán Límite: Aged / Female / Humans / Male / Middle aged Idioma: En Revista: Circulation Año: 2020 Tipo del documento: Article Pais de publicación: Estados Unidos